Targeting bone physiology for the treatment of metastatic prostate cancer

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 3, 2013, Pages 134-143

  Autio, Karen A ^a   Morris, Michael J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Denosumab; Osteoblast; Osteoclast; Radiopharmaceutical; Radium 223; Rankl

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; CABOZANTINIB; CADHERIN; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; KETOCONAZOLE; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; RADIUM CHLORIDE RA 223; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SAMARIUM 153; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; STRONTIUM 89; TRANSFORMING GROWTH FACTOR BETA; VINBLASTINE; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE REMODELING; BONE SCINTISCANNING; BREAST CANCER; CANCER GROWTH; CELL EXPANSION; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HYPOCALCEMIA; INCIDENCE; JAW OSTEONECROSIS; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PREVALENCE; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SINGLE DRUG DOSE; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TOXICITY; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; OSTEOCLASTS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84877940529     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality of-life considerations throughout the continuum of care. Eur Urol. 2004;46:731-739.
2. Tannock IF,de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
5. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1989;1:571-573.
6. Weilbaecher KN, Guise T., McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411-425.
7. Bruni-Cardoso A, Johnson LC, Vessella RL, et al. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res. 2010;8:459-470.
8. Nemeth JA, Cher ML, Zhou Z, et al. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis. 2003;20:413-20.
9. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem. 2007;101:873-886.
10. Clarke NW, McClure J, George NJ. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol. 1993;24:286-290.
11. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol. 2010;37(suppl 2):S2-S14.
12. Zheng D-Q, Woodward AS, Fornaro M, et al. Prostatic carcinoma cell migration via αvβ3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 1999;59:1655-1664.
13. Edlund M, Miyamoto T, Sikes RA, et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ. 2001;12:99-107.
14. Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone. 2011;48:54-65.
15. McCabe NP, De S, Vasanji A, et al. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene. 2007;26:6238-6243.
16. van den Hoogen C, van der Horst G, Cheung H, et al. Integrin alpha-v expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol. 2011;179:2559-2568.
17. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
18. Liao J, Schneider A, Datta NS, et al. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 2006;66:9065-9073.
19. Sanders JL, Chattopadhyay N, Kifor O, et al. Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endocrinol Metab. 2001;281:E1267-E1274.
20. Saidak Z, Mentaverri R, Brown EM. The role of the calcium-sensing receptor in the development and progression of cancer. Endocr Rev. 2009;30:178-195.
21. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate. 2006;66:32-48.
22. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462-473.
23. Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res. 2005;20:318-329.
24. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:87994.
25. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colonystimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767-4773.
26. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720-5726.
27. Dubrovska A, Elliott J, Salamone RJ, et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One. 2012;7:e31226.
28. Cai J, Kandagatla P, Singareddy R, et al. Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Transl Oncol. 3:195-203.
29. Yu J, Mani RS, Cao Q, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17:443-454.
30. Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol. 2012;351:249-263.
31. Morgan TM, Lange PH, Porter MP, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15:677-683.
32. Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci. 2007;12:3000-3009.
33. Weckermann D, Polzer B, Ragg T, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549-1556.
34. Berg A, Berner A, Lilleby W, et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer. 2007;120:1603-1609.
35. Davis JW, Nakanishi H, Kumar VS, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008;179:2187-2191.
36. Helo P, Cronin AM, Danila DC, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem. 2009;55:765-773.
37. Sun P, Xiong H, Kim TH, et al. Positive inter-regulation between betacatenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells. Mol Pharmacol. 2006;69:520-531.
38. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003;169:1143-1149.
39. Huang CF, Lira C, Chu K, et al. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010;70:4580-4589.
40. Lee YC, Cheng CJ, Huang M, et al. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010;221:68-76.
41. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004;2:499-506.
42. Quax PH,de Bart AC, Schalken JA et al. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. Prostate. 1997;32:196-204.
43. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287-5297.
44. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst. 2002;94:17-25.
45. Annabi B, Bouzeghrane M, Currie JC, et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis. 2005;22:429-439.
46. Chen PS, Shih YW, Huang HC, et al. Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One. 2011;6:e20164.
47. Kondo H, Guo J, Bringhurst FR. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res. 2002;17:1667-1679.
48. Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15:960-966.
49. Wan X, Li ZG, Yingling JM, et al. Effect of transforming growth factor beta (TGFbeta) receptor I kinase inhibitor on prostate cancer bone growth. Bone. 2012;50:695-703.
50. Zhau HE, Odero-Marah V, Lue HW, et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis. 2008;25:601-610.
51. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981-991.
52. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792-4798.
53. Verras M, Brown J, Li X, et al. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 2004;64:8860-8866.
54. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65:7554-7560.
55. Masiello D, Chen SY, Xu Y, et al. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol. 2004;18:2388-2401.
56. Liu XH, Kirschenbaum A, Yao S, et al. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res. 2007;67:5747-5753.
57. Yang F, Li X, Sharma M, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem. 2002;277:1136-1144.
58. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961-2978.
59. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53-62.
60. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-5139.
61. www.ClinicalTrials.gov. A randomized double-blind, placebo-controlled phase III study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone. http://clinicaltrials.gov/ct2/show/NCT00079001. Identifier: NCT00079001.
62. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813-822.
63. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39-46.
64. Logothetis CJ. Treatment of prostate cancer metastases: more than semantics. Lancet. 2012;379:4-6.
65. Furlow B. US FDA advisory panel rejects early denosumab therapy. Lancet Oncol. 2012;13:e94.
66. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.
67. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
68. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341-1347.
69. www.Controlled-Trials.com. Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients: a randomised, open-label, multicentre study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). http://www.controlled-trials. com/ISRCTN66626762/zeus. Identifier: ISRCTN66626762.
70. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392-400.
71. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-341.
72. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebocontrolled clinical trial. J Clin Oncol. 1998;16:1574-1581.
73. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-955.
74. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109:637-643.
75. Tu SM, Mathew P, Wong FC, et al. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castrationresistant metastatic prostate cancer. J Clin Oncol. 2009;27:3319-3324.
76. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:2436-2442.
77. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429-2435.
78. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451-4459.
79. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebocontrolled phase II study. Lancet Oncol. 2007;8:587-594.
80. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678-686.
81. Nilsson S. Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28: Abstract 4678.
82. Parker C, Heinrich D, Sullivan JM, et al. Overall survival benefit of Radium 223 Chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castrate resistant prostate cancer: a phase III randomized trial. Eur J Cancer. 2011;47: Abstract 1LBA.
83. www.ClinicalTrials.gov. A Phase I/IIa Study of Safety and Efficacy of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer. http://clinicaltrials.gov/show/NCT01106352. Identifier: NCT01106352.
84. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
85. Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 2010;9:9.
86. Russo AL, Jedlicka K, Wernick M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res. 2009;15:4292-4298.
87. Gupta A, Karakiewicz PI, Roehrborn CG, et al. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 2008;14:7385-7390.
88. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60:1113-1117.
89. Hussain M, Smith M, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2011;29: Abstract 4516.
90. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
91. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
92. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.